Top Markets
#1 PulseChain PulseChain +45.01%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.92%
#3 RedStone RedStone +15.11%
#4 Meteora Meteora +9.03%
#5 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.09%
#6 SkyAI SkyAI +7.96%
#7 Unit Pump Unit Pump +7.79%
#8 Pump.fun Pump.fun +7.79%
#9 Lighter Lighter +7.66%
#10 Lista DAO Lista DAO +7.22%
Coin of the day
PulseChain PulseChain
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rang in aandelen #28042
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Aandeelprijs
$0.55
Laatst gesynchroniseerd: 2025-02-11
Marktkapitalisatie
$28.90M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Categorie

Healthcare
Operationele marge voor Marinus Pharmaceuticals, Inc. (MRNS)
Operationele marge op August 2026 TTM: -424.30%
Volgens de meest recente financiële rapporten en aandelenkoers van Marinus Pharmaceuticals, Inc. is de huidige operationele marge (TTM) -424.30%. Eind 2022 had het bedrijf een operationele marge van -442.69%.
Geschiedenis van de operationele marge van Marinus Pharmaceuticals, Inc. van 2012 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.